Events

Recall of Devices for carrying out endovascular manipulations

According to Federal Service for Surveillance in Healthcare, this recall involved a device in Russian Federation that was produced by ev3 inc..

What is this?

A correction or removal action taken by a manufacturer to address a problem with a medical device. Recalls occur when a medical device is defective, when it could be a risk to health, or when it is both defective and a risk to health.

Learn more about the data here
  • Type of Event
    Recall
  • Event ID
    01И-2244/16, РЗН 2015/2741
  • Date
    2016-11-16
  • Event Date Posted
    2016-11-16
  • Event Country
    Russian Federation
  • Event Source
    FSSH
  • Event Source URL
    http://www.roszdravnadzor.ru/services/unreg
  • Notes / Alerts
    Russian data is current through January 2019. All of the data comes from the Federal Service for Surveillance in Healthcare, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Russia.
  • Extra notes in the data
    Manufacturer Recall

Device

Devices for carrying out endovascular manipulations

Manufacturer

ev3 inc.
  • Manufacturer Parent Company (2017)
    Medtronic plc
  • Manufacturer comment
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    FSSH